- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00971984
Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern Israel
August 30, 2015 updated by: Dr Koren Ariel, HaEmek Medical Center, Israel
The study intends to summarize the clinical and laboratory characteristics of children with hemolytic anemia diagnosed as having alpha thalassemia mutations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Fifty children and adolescents diagnosed as having alpha thalassemia will be studied, the clinical characteristics and hematology analysis will be summarized.
Study Type
Observational
Enrollment (Actual)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Afula, Israel, 18101
- Pediatric Hematology Unit and Pediatric Dpt B - HaEmek Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 20 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
A group of 50 children that underwent workup due to hemolytic anemia and were further diagnosis as suffering from clinical alpha thalassemia.
Description
Inclusion Criteria:
- All the patients that were studied at the pediatric hematology unit ant the Ha'Emek Medical Center
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Alpha thalassemia patients
Patients diagnosed with alpha thalassemia mutations and anemia
|
Summary of Medical files and laboratory results.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of the Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia
Time Frame: One year
|
Analysis of the Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia
|
One year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
April 1, 2012
Study Completion (Actual)
April 1, 2012
Study Registration Dates
First Submitted
September 3, 2009
First Submitted That Met QC Criteria
September 3, 2009
First Posted (Estimate)
September 4, 2009
Study Record Updates
Last Update Posted (Estimate)
September 1, 2015
Last Update Submitted That Met QC Criteria
August 30, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0074-09-EMC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemolytic Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
-
Alexion PharmaceuticalsTerminatedWarm Autoimmune Hemolytic AnemiaUnited States, Jordan
-
Novartis PharmaceuticalsRecruitingWarm Autoimmune Hemolytic Anemia (wAIHA)China, Japan, Spain, Singapore, France, Germany, Taiwan, United States, Italy, India, Malaysia, Argentina, Hungary, Israel, Australia, Thailand, United Kingdom, Romania
-
Annexon, Inc.CompletedWarm Autoimmune Hemolytic Anemia (wAIHA)United States
-
Eugene NikitinUnknownAIHA - Warm Autoimmune Hemolytic AnemiaRussian Federation
-
Institute of Hematology & Blood Diseases Hospital...RecruitingRefractory/Relapsed Autoimmune Hemolytic AnemiaChina
Clinical Trials on Medical records summary
-
Severance HospitalCompletedKidney TransplantationKorea, Republic of
-
Agency for Healthcare Research and Quality (AHRQ)University of Illinois at ChicagoCompletedInterprofessional Relations | Information DisseminationUnited States
-
HaEmek Medical Center, IsraelUnknownThrombosis | PrematureIsrael
-
HaEmek Medical Center, IsraelCompletedSickle Cell Anemia | ThalassemiaIsrael
-
Hamad Medical CorporationCompletedChronic Kidney Diseases | Acute Kidney Injury | COVID-19 Pandemic | COVID-19 Infection | Chronic Renal Failure in ChildrenQatar
-
Peking University Third HospitalActive, not recruiting
-
Cairo UniversityCompleted
-
University Hospital, MontpellierCompleted
-
National Taiwan University HospitalUnknownPelvic Organ ProlapseTaiwan
-
Meir Medical CenterCompletedFemoral Neck FracturesIsrael